Received Apr 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
Pain and redness at injection site that is still worsening after two days; Pain and redness at injection site that is still worsening after two days; This non-serious case was reported by a consumer and described the occurrence of injection site erythema in a 78-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Concurrent medical conditions included hypothyroidism and blood cholesterol increased. Concomitant products included atorvastatin calcium (Atorvastatin) and levothyroxine sodium (Levothyroxine). On 25-APR-2025, the patient received Shingrix .5 ml. On 25-APR-2025, less than a day after receiving Shingrix, the patient experienced injection site erythema (Verbatim: Pain and redness at injection site that is still worsening after two days) and injection site pain (Verbatim: Pain and redness at injection site that is still worsening after two days). The outcome of the injection site erythema and injection site pain were not resolved. It was unknown if the reporter considered the injection site erythema and injection site pain to be related to Shingrix. It was unknown if the company considered the injection site erythema and injection site pain to be related to Shingrix. Additional Information: GSK receipt date: 27-APR-2025 The patient experienced pain and redness at injection site that was still worsening after two days. These symptoms were not treated.
Blood cholesterol increased; Hypothyroidism
Atorvastatin; Levothyroxine